1. Signaling Pathways
  2. Epigenetics
    TGF-beta/Smad
  3. PKC
  4. PKCι Isoform
  5. PKCι Inhibitor

PKCι Inhibitor

PKCι Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-106381
    Aurothiomalate sodium
    Inhibitor ≥98.0%
    Aurothiomalate sodium is a potent and selective oncogenic PKCι signaling inhibitor. Aurothiomalate sodium inhibits tumor cell proliferation and not cell apoptosis. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium, an anti-rheumatoid agent, exhibits potent anti-tumor activity.
  • HY-122858A
    PKCiota-IN-2 formic
    Inhibitor 99.23%
    PKCiota-IN-2 formic is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.8 nM. PKCiota-IN-2 formic also inhibits PKC-α and PKC-ε with IC50s of 71 nM and 350 nM, respectively.
  • HY-117366
    PS432
    Inhibitor ≥99.0%
    PS432 is a PKC inhibitor with IC50s of 16.9 μM (PKCι) and 18.5 μM (PKCζ), respectively. PS432 effectively inhibits the proliferation of non-small cell lung cancer cells (NSCLCs) and tumor growth in mouse xenograft models.
  • HY-122858
    PKCiota-IN-2
    Inhibitor
    PKCiota-IN-2 is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.8 nM. PKCiota-IN-2 also inhibits PKC-α and PKC-ε with IC50s of 71 nM and 350 nM, respectively.
  • HY-122857
    PKCiota-IN-1
    Inhibitor
    PKCiota-IN-1 (compound 51) is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.7 nM. PKCiota-IN-1 also inhibits PKC-α and PKC-ε with IC50s of 45 nM and 450 nM, respectively.